[go: up one dir, main page]

FR2722991B1 - USE OF BETA2-GLYCOPROTEIN I IN AT LEAST ONE OF ITS FORMS AS ANTI-INFECTIVE AGENT AND CORRESPONDING PHARMACEUTICAL COMPOSITION - Google Patents

USE OF BETA2-GLYCOPROTEIN I IN AT LEAST ONE OF ITS FORMS AS ANTI-INFECTIVE AGENT AND CORRESPONDING PHARMACEUTICAL COMPOSITION

Info

Publication number
FR2722991B1
FR2722991B1 FR9409527A FR9409527A FR2722991B1 FR 2722991 B1 FR2722991 B1 FR 2722991B1 FR 9409527 A FR9409527 A FR 9409527A FR 9409527 A FR9409527 A FR 9409527A FR 2722991 B1 FR2722991 B1 FR 2722991B1
Authority
FR
France
Prior art keywords
beta2
glycoprotein
forms
pharmaceutical composition
infective agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9409527A
Other languages
French (fr)
Other versions
FR2722991A1 (en
Inventor
Elie Stefas
Marcel Rucheton
Hubert Graafland
Franscico Veas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Recherche pour le Developpement IRD
Original Assignee
Institut de Recherche pour le Developpement IRD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Recherche pour le Developpement IRD filed Critical Institut de Recherche pour le Developpement IRD
Priority to FR9409527A priority Critical patent/FR2722991B1/en
Priority to PCT/FR1995/001030 priority patent/WO1996004006A1/en
Publication of FR2722991A1 publication Critical patent/FR2722991A1/en
Application granted granted Critical
Publication of FR2722991B1 publication Critical patent/FR2722991B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR9409527A 1994-08-01 1994-08-01 USE OF BETA2-GLYCOPROTEIN I IN AT LEAST ONE OF ITS FORMS AS ANTI-INFECTIVE AGENT AND CORRESPONDING PHARMACEUTICAL COMPOSITION Expired - Fee Related FR2722991B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9409527A FR2722991B1 (en) 1994-08-01 1994-08-01 USE OF BETA2-GLYCOPROTEIN I IN AT LEAST ONE OF ITS FORMS AS ANTI-INFECTIVE AGENT AND CORRESPONDING PHARMACEUTICAL COMPOSITION
PCT/FR1995/001030 WO1996004006A1 (en) 1994-08-01 1995-07-31 USE OF AT LEAST ONE FORM OF THE β2-GLYCOPROTEIN I AS AN ANTI-INFECTIOUS AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9409527A FR2722991B1 (en) 1994-08-01 1994-08-01 USE OF BETA2-GLYCOPROTEIN I IN AT LEAST ONE OF ITS FORMS AS ANTI-INFECTIVE AGENT AND CORRESPONDING PHARMACEUTICAL COMPOSITION

Publications (2)

Publication Number Publication Date
FR2722991A1 FR2722991A1 (en) 1996-02-02
FR2722991B1 true FR2722991B1 (en) 1996-10-11

Family

ID=9465959

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9409527A Expired - Fee Related FR2722991B1 (en) 1994-08-01 1994-08-01 USE OF BETA2-GLYCOPROTEIN I IN AT LEAST ONE OF ITS FORMS AS ANTI-INFECTIVE AGENT AND CORRESPONDING PHARMACEUTICAL COMPOSITION

Country Status (2)

Country Link
FR (1) FR2722991B1 (en)
WO (1) WO1996004006A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
JP5127043B2 (en) 2005-01-24 2013-01-23 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム FC fusion constructs that bind to phosphatidylserine and their therapeutic uses

Also Published As

Publication number Publication date
FR2722991A1 (en) 1996-02-02
WO1996004006A1 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
BR9800344A (en) Glass composition and use of glass compositions
EP0793501A4 (en) 'IN VIVO' ACTIVATION OF TUMOR-SPECIFIC-CYTOTOXIC T-CELLS
BR9509200A (en) Composition of matter
BR9608857A (en) Liquid composition and liquid detergent
BR9702517A (en) Use of polymer composition and process
BR9509716A (en) Composition of pleat reduction
DE69836008D1 (en) COMPOSITION AND TREATMENT AGENT
PT907364E (en) PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERTACAO
FI971495A0 (en) Defoamer composition and method of use
FR2772609B1 (en) USE OF AT LEAST ONE AUXIN IN A COSMETIC COMPOSITION
FR2740333B1 (en) USE OF A SUBSTANCE P ANTAGONIST IN A TOPICAL COMPOSITION AS AN ANTITRANSPIRANT AGENT
FR2751540B1 (en) ANTITHROMBOTIC PHARMACEUTICAL COMPOSITION
FR2749589B1 (en) COATING COMPOSITION AND USES IN THE FOOD AND PHARMACEUTICAL INDUSTRY
BR9502407A (en) Lubricating and concentrated composition
EE9800234A (en) Method of treatment and pharmaceutical composition
ATE204177T1 (en) USE OF SUBSTANCE P ANTAGONIST IN PHARMACEUTICAL COMPOSITION
FR2754449B1 (en) USE OF OXAZOLIDINONE DERIVATIVES AS ANTI-PENETRATING AGENTS IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION
BR9505381A (en) Use of at least one substance p antagonist and use of one substance p antagonist
BR9509688A (en) Pharmaceutical composition and composition
ID19428A (en) COMPOSITION OF AMINO ACID COMPOSITION AND ITS USE IN IMPRESSION OF IMMUNITY
FR2722991B1 (en) USE OF BETA2-GLYCOPROTEIN I IN AT LEAST ONE OF ITS FORMS AS ANTI-INFECTIVE AGENT AND CORRESPONDING PHARMACEUTICAL COMPOSITION
BR9604938A (en) Recombinant virus deficient use of this virus pharmaceutical composition and mammalian cell
FR2772610B1 (en) USE OF CINNAMIC ACID OR AT LEAST ONE OF ITS DERIVATIVES IN A COSMETIC COMPOSITION
ID23156A (en) AMIDINA'S DEMONSTRATIONS, THE PROCESS OF MAKING COMPOSITION AND ITS USE
BR9509055A (en) Imidazoloquinoxalinone use of the same and pharmaceutical composition

Legal Events

Date Code Title Description
CL Concession to grant licences
ST Notification of lapse

Effective date: 20120430